Development and Implementation of Dried Blood Spot-Based COVID-19 Serological Assays for Epidemiologic Studies.
COVID-19
SARS-CoV-2
antibodies
dried blood spot
serology
seroprevalence
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
29 06 2022
29 06 2022
Historique:
pubmed:
26
5
2022
medline:
2
7
2022
entrez:
25
5
2022
Statut:
ppublish
Résumé
Serological surveillance studies of infectious diseases provide population-level estimates of infection and antibody prevalence, generating crucial insight into population-level immunity, risk factors leading to infection, and effectiveness of public health measures. These studies traditionally rely on detection of pathogen-specific antibodies in samples derived from venipuncture, an expensive and logistically challenging aspect of serological surveillance. During the COVID-19 pandemic, guidelines implemented to prevent the spread of SARS-CoV-2 infection made collection of venous blood logistically difficult at a time when SARS-CoV-2 serosurveillance was urgently needed. Dried blood spots (DBS) have generated interest as an alternative to venous blood for SARS-CoV-2 serological applications due to their stability, low cost, and ease of collection; DBS samples can be self-generated via fingerprick by community members and mailed at ambient temperatures. Here, we detail the development of four DBS-based SARS-CoV-2 serological methods and demonstrate their implementation in a large serological survey of community members from 12 cities in the East Bay region of the San Francisco metropolitan area using at-home DBS collection. We find that DBS perform similarly to plasma/serum in enzyme-linked immunosorbent assays and commercial SARS-CoV-2 serological assays. In addition, we show that DBS samples can reliably detect antibody responses months postinfection and track antibody kinetics after vaccination. Implementation of DBS enabled collection of valuable serological data from our study population to investigate changes in seroprevalence over an 8-month period. Our work makes a strong argument for the implementation of DBS in serological studies, not just for SARS-CoV-2, but any situation where phlebotomy is inaccessible.
Identifiants
pubmed: 35612315
doi: 10.1128/spectrum.02471-21
pmc: PMC9241704
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0247121Références
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):700
pubmed: 29143672
PLoS One. 2020 Aug 14;15(8):e0237833
pubmed: 32797108
Microbiol Spectr. 2021 Oct 31;9(2):e0129821
pubmed: 34668728
EBioMedicine. 2021 Aug;70:103502
pubmed: 34333234
Nat Commun. 2021 Jul 19;12(1):4383
pubmed: 34282139
Am J Trop Med Hyg. 2018 Aug;99(2):256-265
pubmed: 29968557
Sci Rep. 2020 Nov 19;10(1):20188
pubmed: 33214612
Transfusion. 2021 Sep;61(9):2677-2687
pubmed: 34121205
J Clin Microbiol. 1992 May;30(5):1179-82
pubmed: 1583117
J Clin Virol. 2021 Mar;136:104739
pubmed: 33588354
Ann Clin Biochem. 2021 Mar;58(2):123-131
pubmed: 33269949
Bioanalysis. 2021 Jan;13(1):13-28
pubmed: 33319585
J Clin Microbiol. 2019 Dec 23;58(1):
pubmed: 31666365
Ann Intern Med. 2021 May;174(5):655-662
pubmed: 33481642
Vaccines (Basel). 2021 Sep 28;9(10):
pubmed: 34696200
Vaccines (Basel). 2021 Oct 03;9(10):
pubmed: 34696233
J Public Health (Oxf). 2022 Jun 27;44(2):e260-e263
pubmed: 33611565
Emerg Infect Dis. 2020 Dec;26(12):2970-2973
pubmed: 32969788
Emerg Infect Dis. 2021 May;27(5):1330-1342
pubmed: 33657340
Nat Commun. 2021 Jun 17;12(1):3695
pubmed: 34140485
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Proc Natl Acad Sci U S A. 2021 Aug 24;118(34):
pubmed: 34376550
Clin Infect Dis. 2021 Dec 16;73(12):2155-2162
pubmed: 33624751
World J Gastroenterol. 2016 Sep 7;22(33):7604-12
pubmed: 27672281
Lancet Infect Dis. 2015 Sep;15(9):1005
pubmed: 26333329
Cell Host Microbe. 2021 Jun 9;29(6):917-929.e4
pubmed: 33984285